Home > Insider Trading > Filing (0001179110-10-011553)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322734	Advanced Life Sciences Holdings Inc.	ADLS	Biological Products, (No Disgnostic Substances) (2836)	300296543

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1229826	A Richard Reck	1440 Davey Road Woodridge IL 60517		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-07-07	1,190,000	$0.04	1,290,000	No	4	P	Indirect	1,270,000 By Self as Trustee of Richard A Reck Trust; 20,000 by Self as Trustee of Daniel Reck Trus

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	1,270,000 By Self as Trustee of Richard A Reck Trust; 20,000 by Self as Trustee of Daniel Reck Trus

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant	Acquisiton	2010-07-07	1,190,000	$0.00	1,190,000	$0.04
Units	Unit Warrant	Acquisiton	2010-07-07	11,900	$0.00	11,900	$4.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,190,000	2011-01-07	2015-07-07	No	4	P	Indirect
11,900			No	4	P	Indirect

Footnotes

On July 7, 2010, Mr. Reck purchased at a price of $4.20 per unti, 11,900 units consisting of, in the aggregate, (i) 1,190,000 shares of the Company's common stock, (ii) warrants to purchsae 1,190,000 shares of common stock at an exercise price of $0.042 per share (the "Stock Warrants") and (iii) warrants to purchase an additional 11, 900 units, with each unit consisting of 100 shares of common stock and 100 Stock Warrants, at an exercise price of $4.20 per additional unit (the "Unit Warrants".
The Stock Warrants may be exercised at any time during the period commening six months after the closing date and ending on the fifth anniversary of the closing date. The Unit Warrants may be exercised at any time during the period commencing on the closing date and ending on the earlier of: (i) the date that is 45 days after the Company's first public announcement that the FDA has accepted the Company's Special Protocol Assessment relating to the additional clinical data needed for regulatory approval in the treatment of community acquired bacterial pneumonia and (ii) December 31, 2010.
Each Unit consists of 100 shares of common stock and 100 Stock Warrants.